An early
proof-of-concept study presented shows promising results for imatinib
mesylate in the treatment of pulmonary arterial hypertension (PAH), a
severe, incurable blood vessel disorder.
Preliminary findings from a 59-patient, multi-center Phase II clinical
trial suggest imatinib mesylate provides a treatment benefit, as
demonstrated by a significant improvement in pulmonary vascular